References
- Aisen, P. S. (2002). Anti-inflammatory agents in Alzheimer's disease.Curr. Neurol. Neurosci. Rep. 2(5):405–409. [PUBMED], [INFOTRIEVE], [CSA]
- Aisen, P. S., Marin, D. B., Brickman, A. M., Santoro, J., Fusco, M. (2001). Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease.Alzheimer Dis. Assoc. Disord. 15(2):96–101. [PUBMED], [CSA], [CROSSREF]
- Citron, M. (2004). Strategies for disease modification in Alzheimer's disease.Nat. Rev., Neurosci. 5:677–685. [CSA], [CROSSREF]
- Dave, K. R., Syal, A. R., Katyare, S. S. (2000). Tissue cholinesterases. A comparative study of their kinetic properties.Z. Naturforsch. 55:100–108. [CSA]
- Dawson, L. J., Caulfield, V. L., Stanbury, J. B., Field, A. E., Christmas, S. E., Smith, P. M. (2005). Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase.Rheumatology 44(4):449–455. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Deepalakshmi, P. D., Parasakthy, K., Shanti, S., Devrajan, N. S. (1994). Effect of chloroquine on rat liver mitochondria.Indian J. Exp. Biol. 32:797–802. [PUBMED], [INFOTRIEVE], [CSA]
- Dixon, M., Webb, E. C. (1979). In: Dixon, M., Webb, E. C., Thorne, C. Jr, Tipton, K. F., eds. Enzymes. 3rd ed. London: Longman.
- Ellman, G. L., Courtny, K. D., Anders, V., Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity.Biochem. Pharmacol. [CSA]
- Farias, G. G., Godoy, J. A., Vazquez, M. C., Adani, R., Meshulam, H., Avila, J., Amitai, G., Inestrosa, N. C. (2005). The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.Neurobiol. Dis. 18:176–183. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hanahan, D. J., Ekholm, J. F. (1978). The expression of optimum ATPase activities in human erythrocytes, a comparison of different lytic procedures.Arch. Biochem. Biophys. 187:170–179. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Inglis, F. (2002). The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.Int. J. Clin. Pract., Suppl. 127:45–63. [CSA]
- Int' Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M., Stricker, B. H. (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease.N. Engl. J. Med. 645:1515–1521. [CSA]
- Jann, M. W., Shirley, K. L., Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.Clin. Pharmacokinet. 41:719–739. [PUBMED], [INFOTRIEVE], [CSA]
- Jarzyna, R., Lenarcik, E., Bryla, J. (1997). Chloroquine is a potent inhibitor of glutamate dehydrogenase in liver and kidney-cortex of rabbit.Pharmacol. Res. 35(1):79–84. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lim, L. Y., Go, M. L. (1985). The anticholinesterase activity of mefloquine.Clin. Exp. Pharmacol. Physiol. 12(5):527–531. [PUBMED], [INFOTRIEVE], [CSA]
- Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951). Protein measurement with folin-phenol reagent.J. Biol. Chem. 193:265–272. [PUBMED], [INFOTRIEVE], [CSA]
- Luo, C., Saxena, A., Ashani, Y., Leader, H., Radic, Z., Taylor, P., Doctor, B. P. (1999). Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime.Chem.-Biol. Interact. 119–120:129–135. [PUBMED], [CSA], [CROSSREF]
- (1998). Markesbery, W. R., ed. Neuropathology of Dementing Disorder. London: Arnold.
- Masson, P., Froment, M., Bartels, F. C., Lockridge, O. (1996). Asp 70 in the peripheral anionic site of human butyrylcholinesterase.Eur. J. Biochem. 235:36–48. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Massoulie, J., Pezzeminti, L., Bon, S., Krejci, E., Vallette, F. (1993). Molecular and cellular biology of cholinesterases.Prog. Neurobiol. 41:31–91. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mc Geer, E. G., Mc Geer, P. L. (1997). The role of the immune system in neurodegenerative disorders.Mov. Disord. 12:855–858. [CSA], [CROSSREF]
- Millerd, C. B., Lockridge, O., Broomfield, C. A. (1998). Organophosphorous acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in somanase.Biochemistry 37:237–247. [CSA], [CROSSREF]
- Morihara, T., Chu, T., Ubeda, O., Beech, W., Cole, G. M. (2002). Selective inhibitions of Aβ42 induction by NSAIDs R-enantiomers.J. Neurochem. 83:1009–1012. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Saxena, A., Redman, A. M.G., Jiang, X., Lockridge, O., Doctor, B. P. (1997). Differences in the active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase.Biochemistry 36:14642–14651. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Scult, K. R., Gilman, A. L. (1997). The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.Leuk. Lymphoma 24:201–210. [CSA]
- Taylor, P. (2001). Anticholinesterase agents. In: Gilmann, A. G., Rall, T. W., Nies, A. S., Taylor, P., eds. The Pharmacological Basis of Therapeutics. 10th ed. New York: Pergamon Press, pp. 175–191.
- Tracy, J. W., Leslie, T. W. Jr. (2001). Drugs used in the chemotherapy of protozoal infections—malaria. In: Gilmann, A. G., Rall, T. W., Nies, A. S., Taylor, P., eds. The Pharmacological Basis of Therapeutics. 10th ed. New York: Pergamon Press, pp. 1069–1109.
- Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Maquez-Sterling, N., Gollde, T. E., Koo, E. H. (2001). A subset of NSAID lower amyloidogenic Aβ42 independently of cyclooxygenase activity.Nature 414:212–216. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yasojima, K., Schwab, C., Mc Geer, E. G., Mc Geer, P. L. (1999). Up-regulated production and activation of the compliment system in Alzheimer's disease brain.Am. J. Pathol. 154:927–936. [PUBMED], [INFOTRIEVE], [CSA]
- Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., Paul, S. M., Ni, B. (2003). Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho.Science 302:1215–1217. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]